Magenta Therapeutics is in the biotechnology industry and healthcare sector. The company CEO is Jason Gardner. Magenta Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing novel medicines to bring the curative power of bone marrow transplant.

Previous Intraday Performance:

The MGTA shares had a previous change of 0.43% which opened at 14.30 and closed at 14.18. It moved to an intraday high of 14.81 and a low of 13.49.

Business Wire:  Magenta Therapeutics to Present at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11th

Historical Performance:

Over the last five trading days, MGTA shares returned -0.42% and in the past 30 trading days it returned -1.60%. Over three months, it changed -10.76%. In one year it has changed -2.34% and within that year its 52 week high was 21.00 and its 52 week low was 5.31. MGTA stock is 167.04% above its 52 week low.

Our calculations result in a 200 day moving average of 11.63 and a 50 day moving average of 15.67. Right now, MGTA stock is trading 21.93% above its 200 day moving average.

Business Wire:  Magenta Therapeutics to Present at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11th


The company has a market cap of $557.2m with 39.3m shares outstanding and a float of 37.8m shares. Trading volume was 82,233 shares and has experienced an average volume of 192,766 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for Magenta Therapeutics was -4.22 which ended on 31st of December 2018.

Below was the last reported quarterly diluted earnings per share:

1stQtr 2019Reported 05-09-2019: -0.44
4thQtr 2018Reported 03-19-2019: -0.50
3rdQtr 2018Reported 11-08-2018: -0.49
2ndQtr 2018Reported 08-09-2018: -3.13
1stQtr 2018 -0.52

The long-term trend of the EPS is an important number as it indicates the present value of Magenta Therapeutics.

Indicators Also to Watch:

Based on the latest filings, there is 38.30% of institutional ownership.

The beta was calculated to be 3.18.

SeekingAlpha:  Intra-Cellular Therapies beats by $0.24

Fundamental Numbers:

Based on last reported financials, the company’s return on assets is -64.62% and price-to-book is 4.14.

Company Score Card:

Results are out of six:
 0  : Growth Expectations Result
 6  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here